Gen: Top 25 Biopharmaceutical Enterprises invested in R & D in 2014

Source: Bio Valley, March 3, 2015 Now, large pharmaceutical companies may have been cutting their R & D departments, but biotechnology giants are still increasing R & D investment Gen summarized that the top 25 biomedical enterprises invested 100.441 billion US dollars in R & D this year, of which the top 20 invested 94.108 billion US dollars In fact, pharmaceutical giants are not spending much less on R & D than they did four years ago In 2014, the R & D investment of the top 10 pharmaceutical giants totaled US $69.077 billion, only 1% less than US $69.459 billion in 2011 The R & D investment of six biotech companies in 2011 and 2014 increased by 50% compared with three years ago, a total of US $14.85 billion In contrast, the growth rate of R & D investment of biological companies is larger than that of large pharmaceutical companies There are different reasons for biotech companies to increase their R & D investment, among which the important reason is that it is the last stage of many pre market trials in the near future The most successful example is Geely's sovaldi, which ranked second in the top 25 sales list of Gen in 2014 At the same time, the past period has been a period of M & a boom between large, small and small pharmaceutical enterprises Large enterprises that acquire other companies will also continue to carry out research and development on existing projects of the acquiree In addition, there are also some reasons, for example, the two parties will cooperate in the form of R & D advance payment, promising R & D investment for the partners One company on the list has agreed to pay $1 billion in research and development advances The following table is the top 25 list of Gen's R & D investment in 2014 The data includes each company's R & D investment in 2014 and 2013, as well as the percentage change between the former and the latter Since Merck did not release the R & D data for the whole year of 2014, the list is not listed temporarily.